NEJM Group | LinkedIn (original) (raw)
Book and Periodical Publishing
Waltham, MA 107,452 followers
Transforming tomorrow’s health care practice – with knowledge you need today.
About us
NEJM Group brings together the people and products that have made the New England Journal of Medicine, NEJM AI, NEJM Evidence, NEJM Catalyst, NEJM Journal Watch, and NEJM CareerCenter leaders in providing the medical knowledge health care professionals need to deliver the best patient care. The goal of NEJM Group is to meet the rapidly growing demand for essential medical information and to disseminate that content in new ways to a broader global health care community than ever before. Our publications reach health care professionals around the globe — making connections between clinical science and clinical practice that advance medical knowledge, health care delivery, and patient outcomes. NEJM Group is a division of the Massachusetts Medical Society.
Industry
Book and Periodical Publishing
Company size
201-500 employees
Headquarters
Waltham, MA
Type
Nonprofit
Founded
1812
Specialties
medical publishing, medical education, medical research, clinical research, health care, and public health
Locations
Employees at NEJM Group
Updates
- The enduring myth that alcohol use disorder results from a moral failure continues to influence public and professional views of the condition. However, an estimated 50% of the risk of alcohol use disorder is thought to be inherited. Furthermore, mental health disorders are associated with a doubled risk of alcohol use disorders. Adverse early life experiences and trauma in adult life (e.g., sexual assault or trauma during military service) have been reported to increase risk. Ready availability of alcohol at low cost and widespread outlets are considered additional important risk factors. The World Health Organization global action plan to reduce consumption and harms from alcohol recommends increasing alcohol taxes, setting a minimum age for purchasing alcohol, and limiting hours for the sale of alcohol, among other actions. Consumption of alcohol activates the reward regions of the brain, increasing the release of dopamine, with additional involvement of endogenous opioids, γ-aminobutyric acid (GABA), endocannabinoids, and other neurotransmitters. The reward system projects to the orbitofrontal cortex and provides a pathway for alcohol to influence decision making, including reduced inhibitory control. With repeated exposure, neurotransmitter responses are blunted in the most severe forms of the disorder. As a result, increasing doses of alcohol are needed to produce the same effect (alcohol tolerance), and alcohol withdrawal syndrome emerges when high levels of consumption are reduced or ceased. Pharmacotherapies for the disorder seek to target these neurobiologic changes (shown in figure). Learn more in the Review Article “Identification and Treatment of Alcohol Use Disorder” by Paul Haber, MD, from Royal Prince Alfred Hospital and the University of Sydney: https://nej.md/3PErxWW #Psychiatry
- 𝐍𝐨𝐭𝐚𝐛𝐥𝐞 𝐀𝐫𝐭𝐢𝐜𝐥𝐞𝐬 𝐨𝐟 𝟐𝟎𝟐𝟒: Effects of Semaglutide on Chronic Kidney Disease (CKD) More than half a billion people globally are affected by CKD and are at high risk for kidney failure, cardiovascular events, and death. Renin–angiotensin system (RAS) inhibitors, sodium–glucose cotransporter 2 (SGLT2) inhibitors, and finerenone have been shown to protect the kidneys and reduce the risk of adverse cardiovascular outcomes and therefore are guideline-directed medical therapies for CKD in patients with type 2 diabetes. Semaglutide has been shown to improve glycemic control, lead to weight loss, and reduce cardiovascular events in patients with type 2 diabetes. Its effect on kidney outcomes in patients who also have CKD is incompletely understood. In the FLOW trial, which was presented at the European Renal Association (ERA) Congress in May 2024, researchers assessed whether the glucagon-like peptide 1 (GLP-1) receptor agonist semaglutide was effective in preventing progression of kidney disease in patients with type 2 diabetes and CKD. The researchers found that semaglutide reduced the risk of clinically important kidney outcomes and death from cardiovascular causes in patients with type 2 diabetes and CKD. “This is the first trial to provide clear evidence that adding a GLP-1 agonist to standard-of-care therapy for persons with type 2 diabetes and evidence of chronic kidney disease led to improvements not only in albuminuria but in rate of decline of estimated glomerular filtration rate — which is a hard outcome. It has already led to change in practice.” – Dr. Julie Ingelfinger, Deputy Editor, NEJM Read the full FLOW trial results: https://nej.md/44U3slPDownload the 14 Notable Articles of 2024: https://nej.md/3ZVMZwF #ClinicalTrials #MedicalResearch
- Severe tricuspid regurgitation is associated with disabling symptoms and an increased risk of death. Transcatheter tricuspid-valve replacement reduces tricuspid regurgitation and may provide greater benefits in terms of quality of life, functional capacity, and survival than medical therapy. In the TRISCEND II trial, researchers evaluated the effectiveness and safety of transcatheter tricuspid-valve replacement plus medical therapy as compared with medical therapy alone in patients with severe tricuspid regurgitation. Patients were assigned in a 2:1 ratio to undergo either transcatheter tricuspid-valve replacement plus medical therapy or medical therapy alone. The primary outcome was a hierarchical composite (in rank order) of death from any cause, implantation of a right ventricular assist device or heart transplantation, tricuspid-valve intervention after the index intervention, hospitalization for heart failure, an improvement of at least 10 points in the score on the Kansas City Cardiomyopathy Questionnaire overall summary (KCCQ-OS), an improvement of at least one New York Heart Association (NYHA) functional class, and an improvement of at least 30 m on the 6-minute walk distance. In patients with severe tricuspid regurgitation, transcatheter tricuspid-valve replacement plus medical therapy was superior to medical therapy alone at 1 year, a result that was driven primarily by alleviation of symptoms and improvements in quality of life. Read the full TRISCEND II trial results and Plain Language Summary: https://nej.md/4dTODm5 #ClinicalTrials #MedicalResearch
- 𝐍𝐨𝐭𝐚𝐛𝐥𝐞 𝐀𝐫𝐭𝐢𝐜𝐥𝐞𝐬 𝐨𝐟 𝟐𝟎𝟐𝟒: Omalizumab for Multiple Food Allergies Food allergy affects up to 8% of children and 10% of adults in the United States, and a large percentage of people with food allergies are allergic to multiple foods. Because management has relied on food avoidance and emergency treatment in cases of accidental exposure, quality of life is affected. Omalizumab, a monoclonal anti-IgE antibody, holds promise as a monotherapy for people with multiple food allergies. In a trial involving 180 persons with food allergies, omalizumab was effective in increasing the reaction threshold for peanut and other common food allergens. “This is the first trial to show that a monoclonal antibody to IgE can effectively improve tolerance of multiple foods among children with multiple food allergies. These results are promising for the roughly 10 percent of the population with food allergies who live with constant worry about exposure to common food allergens (nuts, milk, and eggs).” – Dr. Patrick O’Malley, Deputy Editor, NEJM Read “Omalizumab for the Treatment of Multiple Food Allergies” for the full trial results: https://nej.md/4bLW7aSDownload the 14 Notable Articles of 2024: https://nej.md/3ZVMZwF #ClinicalTrials #MedicalResearch
- The latest Double Take video describes the case of a man with persistent diffuse abdominal pain, fatigue, and anorexia with subsequent weight loss. Based on a Clinical Problem-Solving article published in NEJM, the video explores the broad differential diagnosis of abdominal pain and how a clinician could assess a patient with a constellation of nonspecific symptoms to identify a unifying diagnosis. Watch the video: https://nej.md/4h4OQotFurther reading: Clinical Problem-Solving: Led Astray (Young et al., August 5, 2020, issue of NEJM) https://nej.md/3PqfQmP
- NEJM Group reposted this
7,546 followers
1w Edited
The February 2025 issue of NEJM Catalyst Innovations in Care Delivery includes articles, case studies, and research reports on public health programs, maternal and infant health care, community partnerships and grantmaking, cochlear implantation, hybrid and virtual care, cystic fibrosis care, and climate action at academic health systems. 📖 View the issue: https://nej.md/4hhxHIC🎧 Read or listen to From the Editors: Improving Health Care for All https://nej.md/4hcF6sl🤳 Insights Report: Hybrid and Virtual Care: Interest Outstrips Infrastructure https://nej.md/40wFiND with expert advisor John Torous, MD MBI, Beth Israel Deaconess Medical Center💉 In Depth: New York City’s Public Health Program to Provide Immunizations and Primary Care to Immigrant Children and Families https://nej.md/4agB682 by Rishi Sood, Allison Lemkin, Max Hadler, Kelly Sabatino, Michelle Macaraig, Bindy Crouch, NYC Department of Health and Mental Hygiene NYC Department of Homeless Services👂Case Study: Achieving Same-Day Patient Consultation and Cochlear Implantation https://nej.md/4afJa8Y by Ankita Patro, Jourdan Holder, Sabrina Poon, MD, MPH, C.J. Stimson, MD, JD, C. Wright Pinson, David Haynes, Vanderbilt University Medical Center🤰Case Study: D.C. Safe Babies Safe Moms: A Novel, Multigenerational Model to Reduce Maternal and Infant Health Disparities https://nej.md/3C7PK4V by Angela Thomas, DrPH, MPH, MBA, Matthew Biel, Janine Rethy, MD, MPH, IBCLC, FAAP, FABM, Michelle Roett, MD, MPH, Kelly Sweeney McShane, Aza Nedhari, CPM, LGPC, Loral Patchen, PhD, MSN, MA, CNM, IBCLC, MedStar Health, Community of Hope, Mamatoto Village, Georgetown University School of Medicine🧒Article: Innovations in Evaluating Ambulatory Costs of Cystic Fibrosis Care: A Comparative Study Across Multidisciplinary Care Centers in Ireland and the United States https://nej.md/4gVb7FH by Emma Brady (O’ Grady) MPSI, Ryan Perkins, Kate Cullen, Greg Sawicki, Bob Kaplan, Professor Gerardine Doyle, University College Dublin, Harvard Medical School, Children's Health Ireland, Boston Children's Hospital🤝Article: The Cedars-Sinai Community Connect Program: Strategic Partnerships and Innovative Grantmaking https://nej.md/3Wimzms by Katie Hren, LCSW, Emma Cohen, Krystal Green, Christina Harris, MD, Erin Jackson-Ward, DrPH, Cedars-Sinai🏭Commentary: Leaders of Academic Health Systems as Drivers of Climate Action and Sustainability https://nej.md/40nqHUH by William T. Mallon EdD, Natalya Cox, MPH, A. Eugene Washington, Association of American Medical Colleges (AAMC), Duke University Medical Center - 𝐍𝐨𝐭𝐚𝐛𝐥𝐞 𝐀𝐫𝐭𝐢𝐜𝐥𝐞𝐬 𝐨𝐟 𝟐𝟎𝟐𝟒: Twice-Yearly Lenacapavir for HIV Prevention in Women Cisgender women account for approximately half the 1.3 million new human immunodeficiency virus (HIV) infections that occur worldwide each year. However, women’s uptake of, adherence to, and persistence in the use of HIV preexposure prophylaxis (PrEP) medication remains limited worldwide, which underscores the need to develop new options. In the PURPOSE 1 randomized, controlled trial involving women in South Africa & Uganda, twice-yearly subcutaneous lenacapavir was superior to daily oral emtricitabine–tenofovir disoproxil fumarate in preventing HIV infection. “This trial demonstrates a highly effective new therapy that prevents HIV acquisition in women. The challenge now is scalability to those at risk.” – Dr. Lindsey Baden, Deputy Editor, NEJM Read the full PURPOSE 1 trial results: https://nej.md/3zRElVjDownload the 14 Notable Articles of 2024: https://nej.md/3ZVMZwF #ClinicalTrials #MedicalResearch
- 𝗧-𝗰𝗲𝗹𝗹 𝗹𝘆𝘀𝗶𝘀 is a process by which cytotoxic T cells recognize and kill other cells, such as infected or tumor cells. Recognition is mediated by the T-cell receptor (on the T cell) and “foreign” or mutant peptides presented by the HLA class I molecule (on the infected cell or tumor cell). To learn more about this NEJM Illustrated Glossary term, read the 2022 editorial “Targeting Cytotoxic T Cells to Tumor” by Elizabeth Phimister, PhD, and Eric J. Rubin, MD, PhD: https://nej.md/3PSwBGkExplore more terms: https://nej.md/glossary #MedicalResearch
- Among patients with atrial fibrillation, direct-acting oral anticoagulants lower the risk of stroke but increase the risk of bleeding, which limits their use. Recently, accumulating evidence has suggested that activated factor XI (XIa) inhibition could be a safer method of anticoagulation. In the OCEANIC-AF trial involving high-risk patients with atrial fibrillation, researchers assessed whether asundexian would provide a net clinical benefit with respect to preventing stroke and systemic embolism without increasing the risk of major bleeding, as compared with the direct-acting oral anticoagulant apixaban. Adults with atrial fibrillation who were at risk for stroke and bleeding events were randomly assigned to receive either asundexian or apixaban, a factor Xa inhibitor. The primary composite efficacy end point was stroke or systemic embolism. Among high-risk patients with atrial fibrillation, oral asundexian was associated with a higher risk of stroke or systemic embolism than apixaban but a lower risk of major bleeding events. Read the full OCEANIC-AF trial results and Plain Language Summary: https://nej.md/473TRdc #ClinicalTrials #MedicalResearch
- 𝐍𝐨𝐭𝐚𝐛𝐥𝐞 𝐀𝐫𝐭𝐢𝐜𝐥𝐞𝐬 𝐨𝐟 𝟐𝟎𝟐𝟒: Finerenone in Heart Failure with Preserved EF In the FINEARTS-HF trial, which was presented at the 2024 European Society of Cardiology annual meeting, researchers examined the efficacy and safety of finerenone in patients with heart failure with mildly reduced or preserved ejection fraction. In the international, double-blind trial, finerenone resulted in a lower rate of total worsening heart failure events and death from cardiovascular causes than placebo, marking a notable benefit with respect to its primary end point. “This is the first time that a drug from this class has been shown to improve cardiovascular outcomes in a heart disease that has few other guideline-directed medical therapies.” – Dr. Jane Leopold, Deputy Editor, NEJM Full FINEARTS-HF trial results: https://nej.md/470x4ixDownload the 14 Notable Articles of 2024: https://nej.md/3ZVMZwF #ClinicalTrials #MedicalResearch